121 related articles for article (PubMed ID: 6106335)
21. [Catecholamine concentration and metabolism in old age].
Frol'kis VV; Bogatskaia LN; Verkhratskiĭ NS; Voronkov GS
Probl Endokrinol (Mosk); 1975; 21(2):32-8. PubMed ID: 1168905
[TBL] [Abstract][Full Text] [Related]
22. [Some aspects of catecholamine metabolism in diabetes mellitus complicated by angiopathies].
Efimov AS; Skrobonskaia NA
Probl Endokrinol (Mosk); 1973; 19(2):7-12. PubMed ID: 4709433
[No Abstract] [Full Text] [Related]
23. [Interrelationship between the activity of cholinergic processes and catecholamine metabolism in botulin poisoning].
Chesnokova NP
Vopr Med Khim; 1978; 24(4):490-5. PubMed ID: 685193
[TBL] [Abstract][Full Text] [Related]
24. [Catecholamines metabolism in extrapyramidal disorders in children].
Mosunova TG
Zh Nevropatol Psikhiatr Im S S Korsakova; 1977; 77(10):1466-9. PubMed ID: 930491
[TBL] [Abstract][Full Text] [Related]
25. [Characteristics of catecholamine metabolism in patients with endogenic depressions in the process of unloading-diet therapy].
Iurkin MM; Misionzhnik EIu; Polishchuk IuI
Vrach Delo; 1974; 4():105-9. PubMed ID: 4831833
[No Abstract] [Full Text] [Related]
26. Changes in urinary excretion of catecholamines and their metabolites in pediatric dental patients.
Sakuma N; Nagasaka N
ASDC J Dent Child; 1996; 63(2):118-22. PubMed ID: 8708120
[TBL] [Abstract][Full Text] [Related]
27. Electroconvulsive therapy: effect on catecholamine excretion by psychiatric patients.
Messiha FS; Turek I
Res Commun Chem Pathol Pharmacol; 1970 Jul; 1(4):535-46. PubMed ID: 5524262
[No Abstract] [Full Text] [Related]
28. The pattern of urinary catecholamines and their metabolites in Duchenne myopathy, in relation to disease evolution.
Dalmaz Y; Peyrin L; Mamelle JC; Tuil D; Gilly R; Cier JF
J Neural Transm; 1979; 46(1):17-34. PubMed ID: 501348
[TBL] [Abstract][Full Text] [Related]
29. [Catecholamine metabolism in Huntington's chorea (in patients and their phenotypically healthy relatives)].
Magalov ShI; Dadali EL
Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(8):1158-63. PubMed ID: 6452012
[TBL] [Abstract][Full Text] [Related]
30. Biochemistry and the schizophrenia. Old concepts and new hypothesis.
Berger PA
J Nerv Ment Dis; 1981 Feb; 169(2):90-9. PubMed ID: 7009786
[TBL] [Abstract][Full Text] [Related]
31. [Peripheral blood T-lymphocyte and T-lymphocyte subset ratios before and after treatment in schizophrenia patients not taking antipsychotic medication].
Baskak SC; Ozsan H; Baskak B; Devrimci Ozgüven H; Kinikli G
Turk Psikiyatri Derg; 2008; 19(1):5-12. PubMed ID: 18330738
[TBL] [Abstract][Full Text] [Related]
32. [Sensory disorders arising during neuroleptic therapy].
Rovinskaia SA; Revva LI
Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(6):905-9. PubMed ID: 6106339
[TBL] [Abstract][Full Text] [Related]
33. Neurochemical studies on tardive dyskinesia. I. Urinary homovanillic acid and plasma prolactin.
Tripodianakis J; Markianos M; Garelis E
Biol Psychiatry; 1983 Mar; 18(3):337-45. PubMed ID: 6132625
[TBL] [Abstract][Full Text] [Related]
34. The metabolic fate of levodopa in man and animals.
Louis WJ; Doyle AE; Sampson RG
Clin Exp Pharmacol Physiol; 1974; 1(4):341-6. PubMed ID: 4459002
[No Abstract] [Full Text] [Related]
35. [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].
Shiloh R; Weizman A; Weizer N; Dorfman-Etrog P; Munitz H
Harefuah; 2001 May; 140(5):369-73, 456. PubMed ID: 11419053
[TBL] [Abstract][Full Text] [Related]
36. Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia.
Zhang ZJ; Reynolds GP; Ramchand C; Peet M; Shah S
Acta Pharmacol Sin; 2001 Jan; 22(1):76-80. PubMed ID: 11730567
[TBL] [Abstract][Full Text] [Related]
37. [Characteristics of central neurotransmitter metabolism in hereditary extrapyramidal disorders].
Iwanowa-Smolenskaja JA; Barchatowa WP
Neurol Neurochir Pol; 1981; 15(4):377-80. PubMed ID: 7329505
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologic strategies for augmenting cognitive performance in schizophrenia.
Friedman JI; Temporini H; Davis KL
Biol Psychiatry; 1999 Jan; 45(1):1-16. PubMed ID: 9894570
[TBL] [Abstract][Full Text] [Related]
39. An analytical study of catecholamine metabolites by phosphorimetry.
Spann WJ; Mousa JJ; Aaron JJ; Winefordner JD
Anal Biochem; 1973 May; 53(1):154-67. PubMed ID: 4711095
[No Abstract] [Full Text] [Related]
40. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
